Literature DB >> 599839

Renal vascular response to interruption of the renin-angiotensin system in normal man.

N K Hollenberg, G H Williams, K J Taub, I Ishikawa, C Brown, D F Adams.   

Abstract

We assessed the role of the renin-angiotensin system in the response of the renal circulation to restriction of sodium intake in 38 normal patients. Both saralasin (10 to 30 ng/kg/min), an angiotensin antagonist, and SQ 20881 (30 to 300microgram/kg), a converting enzyme inhibitor, induced a dose-related increase in renal blood flow (xenon 133 washout) only when the resin-angiotension system was activated by restriction of sodium intake to 10 MEq/day. Increasing doses of saralasin (100 to 1,000 ng/kg/min) reduced renal blood flow, presumably due to the angiotensin-like action of this partial agonist. The renal vascular response to SQ 20881 paralleled the endocrine response: An identical threshold dose (30 microgram/kg) increased renal blood flow and reduced plasma angiotensin II concentration, which fell despite a progressive rise of plasma renin activity. Plasma bradykinin concentration did not change in response to SQ 20881, which also blocks kininase II. Both agents also induced a small but consistent and statistically significant reduction in arterial blood pressure, which will be important in assessing the pathogenetic significance of a blood pressure reduction in patients with hypertension. This study indicates that angiotensin mediates the renal vascular response to restriction of salt intake in normal man and provides an approach to assessing the role played by angiotensin in the pathogenesis of functional renal disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 599839     DOI: 10.1038/ki.1977.113

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans.

Authors:  John P Forman; Jonathan S Williams; Naomi D L Fisher
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

2.  Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension.

Authors:  A Vaidya; J P Forman; J S Williams
Journal:  J Hum Hypertens       Date:  2010-12-02       Impact factor: 3.012

3.  Labetolol in patients with hypertension and varying degrees of renal impairment.

Authors:  E G Breen; M Lombard; A Watson; J A Keogh
Journal:  Ir J Med Sci       Date:  1984-10       Impact factor: 1.568

4.  A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension.

Authors:  R Wilkinson; I M Stevens; M Pickering; V Robson; T Hawkins; D N Kerr; J D Harry
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

5.  Effect of volume depletion on the afferent arterioles in the avian kidney.

Authors:  I Morild; J A Christensen; O J Halvorsen; M Farstad
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

6.  beta-Adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation.

Authors:  N K Hollenberg; D F Adams; D N McKinstry; G H Williams; L J Borucki; J M Sullivan
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  Effects of interrupting the renin-angiotensin system on sodium excretion in man.

Authors:  J Brown
Journal:  J Physiol       Date:  1988-01       Impact factor: 5.182

8.  The effect of enalapril on the renal response to tilting in humans.

Authors:  N P Lewis; D R Ferguson
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

9.  Abnormal renin short feedback loop in essential hypertension is reversible with converting enzyme inhibition.

Authors:  M s LeBoff; R G Dluhy; N K Hollenberg; T J Moore; R J Koletsky; G H Williams
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

10.  Regional circulatory response to converting-enzyme inhibition in congestive heart failure.

Authors:  D P Faxon; M A Creager; J L Halperin
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.